Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Next Previous
Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-FURTHER
  • Sponsors Centocor

    • Most Recent Events

    • 21 Mar 2022 Results of pooled analysis assessing safety of three studies (NCT00973479, NCT02181673 & NCT02186873) published in the Arthritis Research and Therapy.
    • 16 Feb 2022 Results of population pharmacokinetic and exposure-response model simulations assessing exposure and efficacy for maintenance doses of intravenous Golimumab published in the Clinical Therapeutics
    • 17 Sep 2021 Results of pharmacokinetic (PK) and exposure-response (E-R) modeling assessing whether shortening the IV dosing interval from Q8W to Q6W could reduce disruptions in symptom relief for some RA patients by using data from the Phase 3 GO-FURTHER study, presented at the 2021 American College of Clinical Pharmacology Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top